Nonsteroidal antiinflammatory drugs may affect the presentation and course of community-acquired pneumonia

Chest

Volumn 139, Issue 2, 2011, Pages 387-394

  Voiriot, Guillaume ^a   Dury, Sandra ^a   Parrot, Antoine ^a   Mayaud, Charles ^a,b   Fartoukh, Muriel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LUNG CAVITATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PLEURA EMPYEMA; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; UNIVERSITY HOSPITAL;

EID: 79551589611     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3102     Document Type: Article

References (32)

1. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America;American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(2 suppl 2):S27-S72.
2. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162(9):1059-1064.
3. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax. 2001;56(suppl 4):IV1-IV64.
4. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-248.
5. Laterre PF, Garber G, Levy H, et al; PROWESS Clinical Evaluation Committee. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med. 2005;33(5):952-961.
6. Aronoff DM, Neilson EG. Antipyretics: mechanisms of action and clinical use in fever suppression. Am J Med. 2001;111(4): 304-315. (Pubitemid 32885627)
7. Raherison C, Peray P, Poirier R, et al. Management of lower respiratory tract infections by French general practitioners: the AIR II study. Analyse Infections Respiratoires. Eur Respir J. 2002;19(2):314-319.
8. Taytard A, Daures JP, Arsac P, et al. Management of lower respiratory tract infections by general practitioners in France [in French]. Rev Mal Respir. 2001;18(2):163-170. (Pubitemid 32494309)
9. Esposito AL. Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis. 1984;130(5):857-862.
10. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990;141(1):186-192.
11. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration . N Engl J Med. 1988;318(23):1481-1486.
12. Sordelli DO, Cerquetti MC, Fontán PA, García VE. Pseudomonas aeruginosa pneumonia. Treatment with nonsteroidal antiinflammatory agents to prevent lung tissue damage. Antibiot Chemother. 1989;42:247-253.
13. Brun-Buisson CJ, Saada M, Trunet P, Rapin M, Roujeau JC, Revuz J. Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs. Br Med J (Clin Res Ed). 1985;290 (6484):1786. (Pubitemid 15059214)
14. Legras A, Giraudeau B, Jonville-Bera AP, et al. A multicentre case-control study of nonsteroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. Crit Care. 2009;13(2):R43.
15. Bernard GR, Wheeler AP, Russell JA, et al; The Ibuprofen in Sepsis Study Group. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997; 336(13):912-918.
16. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore). 2003;82(4):225-235.
17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia . N Engl J Med. 1997;336(4):243-250. (Pubitemid 27044625)
18. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European-North American multicenter study. JAMA. 1993;270(24):2957-2963. (Pubitemid 24000804)
19. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
20. Whitney CG, Farley MM, Hadler J, et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343(1917):1924-1924.
21. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1656-1662.
22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-1379. (Pubitemid 27028925)
23. Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis. 2001;33(2):158-165. (Pubitemid 32643329)
24. Moine P, Vercken JB, Chevret S, Gajdos P; The French Study Group of Community-Acquired Pneumonia in ICU. Severe community-acquired pneumococcal pneumonia. Scand J Infect Dis. 1995;27(3):201-206.
25. Marrie TJ, Shariatzadeh MR. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). 2007;86(2):103-111. (Pubitemid 46668059)
26. Menéndez R, Torres A, Zalacaín R, et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11): 960-965.
27. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med. 2000;162(1):154-160. (Pubitemid 30469813)
28. Leroy O, Santré C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med. 1995;21(1):24-31.
29. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;132(4):1348-1355.
30. Chouaib S, Bertoglio JH. Prostaglandins E as modulators of the immune response. Lymphokine Res. 1988;7(3):237-245.
31. Aronoff DM, Canetti C, Peters-Golden M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J Immunol. 2004;173(1):559-565. (Pubitemid 38797384)
32. Serezani CH, Chung J, Ballinger MN, Moore BB, Aronoff DM, Peters-Golden M. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol. 2007;37(5):562-570. (Pubitemid 350058187)